SystImmune’s pipeline includes bi-specific antibodies, tri-specific antibodies, and antibody-drug conjugates (ADCs).

Pipeline

Name
Discovery
POC
Pre-clinical
Phase 1
Immuno-Oncology
SI-B001
- non-small cell lung cancer
Discovery
POC
Pre-clinical
SI-B003 - lung, kidney, and glioblastoma cancers
Discovery
POC
Pre-clinical
SI-T027 - liver cancer and other solid tumors
Discovery
POC
SI-T030 - tumors with TILs
Discovery
POC
SI-T031 - tumors without TILs
Discovery
POC
SI-T034 - blood cancer
Discovery
POC
Antibody Drug Conjugates
SI-M002A - glioblastoma
Discovery
POC
SI-B004A - breast cancer
Discovery
POC
SI-M005A - nasopharyngeal cancer
Discovery
POC
SI-B029A - lung, colon, head, and neck cancers
Discovery
POC
Pre-clinical
Small Molecule Drugs
BLH1-131 (IDO) - lung, colon, head, and neck cancers
Discovery

Pipeline Status

SI-B001: Bi-specific antibodies for the treatment of non-small cell lung cancer. We have completed our small scale process development and are now into a pilot scale production run in preparation for phase I clinical trials. We expect to file an IND at the end of 2017 in the US and in early 2018 in China.

SI-B003: Bi-specific antibodies against two checkpoint inhibitors: We are currently expecting to file our IND in late 2018 in both the US and China.